Characterizing Compounds Targeting Colorectal Cancer Derived From Monastrol Using High-Through Screening of an Extensive Combinatorial Library
Alejandro Rodríguez-Martínez, Lucía Giraldo-Ruiz, Maria C. Ramos, Irene LuqueiD, Diogo Ribeiro, Fátima Postigo-CorralesiD, Begoña Alburquerque-GonzáleziD, Silvia Montoro‐GarcíaiD, Ana Belén Arroyo-Rodríguez, Pablo Conesa‐ZamoraiD, Ana María Hurtado-López, Ginés Luengo‐GiliD, Horacio Pérez‐SáncheziD
Abstract
BackgroundCancer remains a critical global health concern. Among its various forms, colorectal cancer (CRC) stands out due to its high prevalence and mortality rates, emphasizing the urgent need for novel therapeutic agents to enhance treatment efficacy and prolong patient survival. Monastrol, an antimitotic compound known to bind kinesin Eg5, is employed in some cancer therapies. Recent studies have revealed that monastrol also interacts with fascin, a protein implicated in tumor aggressiveness and metastasis, thereby disrupting microtubule dynamics and actin bundling, ultimately impairing cell migration. MethodsIn this work, we developed a workflow to identify fascin-binding compounds based on a monastrol-derived pharmacophore model, integrating in silico predictions with in vitro validation. We performed ligand-based virtual screening using a pharmacophore model constructed from monastrol, applied to a high-throughput screening (HTS) library of 1.6 million compounds. The top-ranking candidates from the virtual screening were subsequently subjected to physicochemical characterization and cellular assays. ResultsTwo compounds (designated Z118298144 and Z17544625) were identified that exhibited strong binding to fascin and inhibited actin bundling in physicochemical assays. Furthermore, cellular experiments demonstrated that both compounds reduced proliferation and impaired migration of CRC cells at micromolar concentrations. ConclusionsWe established an optimized pipeline combining virtual screening with experimental validation to efficiently identify fascin inhibitors. Using this approach, we discovered two promising compounds with anticancer activity in CRC cell cultures. Moreover, the protocol has been successfully adapted for application to additional cancer-related targets, expanding its potential utility in drug discovery. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/667829v1_ufig1.gif" ALT="Figure 1"> View larger version (31K): org.highwire.dtl.DTLVardef@dc470eorg.highwire.dtl.DTLVardef@1bd0759org.highwire.dtl.DTLVardef@12d755dorg.highwire.dtl.DTLVardef@1742d45_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- FWCI
- 0.00
- Field percentile
- top 27%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of Z1362873773: A Novel Fascin Inhibitor from a Large Chemical Library for Colorectal Cancer
Alejandro Rodríguez Martínez, Lucía Giraldo-Ruiz, … Horacio Pérez‐Sánchez·Scientific ReportsPeer-reviewed·Apr 28, 2025
- Computational Identification of Potential Inhibitors Targeting cdk1 in Colorectal Cancer
Uchechukwu Chibuzo Ogbodo, Ojochenemi A. Enejoh, … Olaitan Igbagbo Awe·Frontiers in ChemistryPeer-reviewed·Nov 30, 2023
- Shifting KRAS hotspot mutations inhibition paradigm in colorectal cancer
A. R. Bras, A. Lopes, … A. Preto·bioRxiv·Aug 9, 2023
- Exploring the potential of Celtis aetnensis compounds through Molecular Docking for Hepatocellular carcinoma.
Kavitha K.N., Krosuri Lakshmi Revathi, Tamilamban Tamiraikani·Journal of Population Therapeutics and Clinical PharmacologyPeer-reviewed·Jan 1, 2022
- Enhancing efficacy of the MEK inhibitor trametinib with paclitaxel in KRAS-mutated colorectal cancer
Susmita Ghosh, Fan Fan, … Rajat Bhattacharya·Therapeutic Advances in Medical OncologyPeer-reviewed·Jan 1, 2024
- Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels
I. Kurth, N. Yamaguchi, … S. F. Tavazoie·bioRxiv·Apr 26, 2021